← feed

Is NCT02143635 results overdue?

Yes — results are overdue. Primary completion was 2017-06-20; the FDAAA-801 reporting deadline (2018-06-20) passed 2923 days ago and no results are posted on ClinicalTrials.gov.

Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt

NCT IDNCT02143635 ↗
SponsorNovartis Pharmaceuticals (INDUSTRY)
Public issuerNOVARTIS AG — NVS (CIK 0001114448) best-effort name match, 95% conf — verify on EDGAR ↗
PhasePHASE1
StatusCOMPLETED
Primary completion2017-06-20 (ACTUAL)
Reporting deadline2018-06-20 (completion + 365d)
Days overdue2923
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-06-21 · SHA-256 484a0619c721b99e… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT02143635. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →